Efficacy and safety of apatinib plus immune checkpoint inhibitors and transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma.

J Cancer Res Clin Oncol · 2024 · PMC11230948 · PMID 38976071

Europe PMC DOI

hedged sentence

0.0630

closest p · 1.3× alpha

0.0630

boldest claim

The sentences

did not reach statistical significanceP = 0.063so close (0.05 < p ≤ 0.1)

Comparison between groups revealed that the best response was better in IA-TACE group compared with A-TACE group, but did not reach statistical significance ( P = 0.063).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.